Login / Signup
Periodic benefit-risk evaluation reports have substantial promise to guide patient care and should be made publicly available.
Michael Fralick
Aaron S Kesselheim
Published in:
Pharmacoepidemiology and drug safety (2017)
Keyphrases
</>
big data
adverse drug
machine learning
deep learning
breast cancer risk